ECM
AXSM icon

Everence Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Everence Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
1,265
+115
+10% +$19.9K 0.01% 723
2025
Q4 		$210K Buy
+1,150
New +$161K 0.01% 731

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Everence Capital Management's AXSM Position: Q1 2026 in Review

Everence Capital Management increased its Axsome Therapeutics (AXSM) stake by 10% in Q1 2026, buying an estimated $19.9K and bringing the position to 1,265 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #723.

Everence Capital Management first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Everence Capital Management held 1,265 shares of Axsome Therapeutics worth $214K as of Q1 2026.
  • Everence Capital Management bought 115 Axsome Therapeutics shares in Q1 2026, an estimated $19.9K.
  • Axsome Therapeutics made up 0.01% of Everence Capital Management's portfolio in Q1 2026, its #723 holding.
  • Everence Capital Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.